Drug delivery and active material science company Aptar Pharma, part of AptarGroup Inc (NYSE:ATR), on Tuesday introduced its first nasal spray pump made with bio-based material, now commercially available with consumer healthcare company Haleon plc's (LON/NYSE:HLN) Otrivin brand.

The Freepod pump, manufactured using 52% ISCC PLUS-certified renewable feedstocks such as bio-waste and residual oils, is part of a mass balance approach that results in 60% circular material content for the full nasal spray device.

The bottle component, produced to represent 100% bio-based content under the same approach, complements the pump in reducing reliance on fossil-based plastics.

Manufacturing is carried out at Aptar Pharma's ISCC PLUS-certified site in Mezzovico, Switzerland, with full traceability across the certified supply chain. This innovation supports Haleon's sustainability targets to cut virgin petroleum-based plastic use by 10% by 2025 and by one-third by 2030, based on 2022 benchmarks.

The collaboration builds on a 30-year partnership between Aptar Pharma and Haleon, formerly GlaxoSmithKline Consumer Healthcare.

Future integration of this sustainable packaging approach is expected for Haleon's Otrivin Nasal Mist, launched globally in 2023.